Wave Life Sciences price to book ratio WVE
Market value divided by the book value of the company's net assets, since 2016.
- Today, Nov 2, 2026
- 1.7×
- 10-year median
- 6.3×
- Against its 10-year history
- 1st
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 1.4× to 31.5×
- Peer median
- 2.6×
Wave Life Sciences' price to book ratio is 1.7× as of Nov 2, 2026.
That is below its ten-year median of 6.3×, lower than on 99% of days in the last ten years.
Over that time it ranged from 1.4× in Oct 2026 to 31.5× in Jul 2024.
The median for 10 large drugmakers of a similar size is 2.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.7× | 1.4× | 21.4× |
| 2025 | 23.9× | 4.1× | 23.9× |
| 2024 | 13.9× | 13.9× | 31.5× |
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 12.7× | 3.2× | 14.6× |
| 2021 | 6.2× | 3.6× | 14.9× |
| 2020 | 3.5× | 2.1× | 18.5× |
| 2019 | 4.7× | 3.3× | 21.4× |
| 2018 | 11.7× | 5.6× | 13.7× |
| 2017 | 5.9× | 2.5× | 6.6× |
| 2016 | 4.1× | 1.8× | 6.1× |
Against its peers
Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| WVEWave Life Sciences | 1.7× |
| COLLCollegium Pharmaceutical | 2.5× |
| ABUSArbutus Biopharma | 3.1× |
| ZVRAZevra Therapeutics | 2.8× |
| IRWDIronwood Pharmaceuticals | n/m |
| PBYIPuma Biotechnology | 3.8× |
| ARVNArvinas | 0.9× |
| CRMDCorMedix | 0.9× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| ANABAnaptysbio | 132× |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Wave Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.